Latham & Watkins has advised CHEPLAPHARM AG (CHEPLAPHARM), a leading international platform for well-established branded medicines based in Greifswald, Germany, on all legal aspects of its conversion into a European stock corporation (Societas Europaea, SE). The company now operates under the name CHEPLAPHARM SE.
The mandate comprised corporate law advice on the conversion and advice on the employee involvement procedure in various European countries, as well as providing legal advice in the negotiations with the special negotiating body of the employees, in each case in close coordination and cooperation with the in-house team of CHEPLAPHARM.
Latham & Watkins regularly advises CHEPLAPHARM, most recently on the issuance of a high yield bond and on the acquisition of the worldwide commercial rights (excluding South Korea) for Zyprexa® from Eli Lilly and Company.
The Latham team was led by Munich partner Tobias Leder, with associate Martina Hölzer and Düsseldorf associates Steffen Augschill and Jan Gocha. The Latham team worked closely with CHEPLAPHARM’s in-house team with Head of Legal Jan Klumb and Contract and Committee Manager Sylvia Rupprecht.
